Cases in Head and Neck Cancer

A Multidisciplinary Approach

Bari Hoffman Ruddy, PhD
Henry Ho, MD
Christine Sapienza, PhD
Jeffrey J. Lehman, MD
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>vii</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>viii</td>
</tr>
<tr>
<td>Contributors</td>
<td>ix</td>
</tr>
<tr>
<td>Multimedia List</td>
<td>xv</td>
</tr>
<tr>
<td><strong>Part I. Demographics and Definitions</strong></td>
<td>1</td>
</tr>
<tr>
<td>1 Head and Neck Cancer Demographics and Team Management</td>
<td>3</td>
</tr>
<tr>
<td>Bari Hoffman Ruddy, Jeffrey J. Lehman, Nikhil Rao, Christine Sapienza, and Henry Ho</td>
<td></td>
</tr>
<tr>
<td><strong>Part II. Oral Cavity Cases</strong></td>
<td>19</td>
</tr>
<tr>
<td>2 Lip, Anterior Floor of Mouth, and Mandibular Cancer</td>
<td>21</td>
</tr>
<tr>
<td>Jeff Searl, Terance Ted Tsue, and Douglas A. Girod</td>
<td></td>
</tr>
<tr>
<td>3 Speech and Swallowing After Hemiglossectomy With Radial Forearm Free Flap Reconstruction</td>
<td>31</td>
</tr>
<tr>
<td>Bernice K. Klaben and Keith Casper</td>
<td></td>
</tr>
<tr>
<td>4 Prolonged Dysphagia Following Chemoradiation of the Soft Palate and Tonsillar Fossa</td>
<td>37</td>
</tr>
<tr>
<td>Donna S. Lundy, Mario A. Landera, and Zoukaa B. Saeqi</td>
<td></td>
</tr>
<tr>
<td><strong>Part III. Oropharyngeal Cases</strong></td>
<td>47</td>
</tr>
<tr>
<td>5 Overview of Multidisciplinary Management for Oropharyngeal Cancer</td>
<td>49</td>
</tr>
<tr>
<td>Katherine A. Hutcheson, Kristen B. Pytynia, and G. Brandon Gunn</td>
<td></td>
</tr>
<tr>
<td>6 An Interdisciplinary Approach to the Management of a Patient With Base of Tongue Carcinoma</td>
<td>69</td>
</tr>
<tr>
<td>Vrushali Angadi, Thomas J. Gal, and Joseph C. Stemple</td>
<td></td>
</tr>
<tr>
<td>7 Adenoid Cystic Carcinoma of the Base of Tongue</td>
<td>77</td>
</tr>
<tr>
<td>Annette H. May and Elizabeth Feldman</td>
<td></td>
</tr>
<tr>
<td>8 Minimally Invasive Approach to Treating Cancer of the Base of Tongue</td>
<td>95</td>
</tr>
<tr>
<td>Molly A. Knigge and Timothy M. McCalloch</td>
<td></td>
</tr>
<tr>
<td>9 Management of SCCA of the Base of Tongue</td>
<td>103</td>
</tr>
<tr>
<td>Adam T. Lloyd, Henry Ho, Erin P. Silverman, and Bari Hoffman Ruddy</td>
<td></td>
</tr>
<tr>
<td>10 An Interdisciplinary Approach to the Management of HPV-Positive Tonsil Cancer With Chemoradiation Therapy</td>
<td>111</td>
</tr>
<tr>
<td>Angela L. Campanelli, Jennifer R. Reitz, Wendy D. LeBorgne, and Matthew R. Garrett</td>
<td></td>
</tr>
<tr>
<td><strong>Part IV. Hypopharyngeal and Supraglottic Cases</strong></td>
<td>121</td>
</tr>
<tr>
<td>11 Overview of Multidisciplinary Management for Hypopharyngeal Cancer</td>
<td>123</td>
</tr>
<tr>
<td>Paula A. Sullivan, Ilona Schmalfuss, Charles E. Riggs, Jr., William M. Mendenhall, Elizabeth Leon, and Annette N. Askren; Illustrations by Carl C. Askren</td>
<td></td>
</tr>
<tr>
<td>12 Rare Chondrosarcoma of the Supraglottis</td>
<td>137</td>
</tr>
<tr>
<td>Jonathon O. Russell, Joseph Scharpf, and Claudio F. Milstein</td>
<td></td>
</tr>
</tbody>
</table>
Part V. Laryngeal Cases

13 Management of SCCA In Situ in a Professional Performer
   Adam T. Lloyd, Erin P. Silverman, and Brian C. Spector

14 Management of Recurrent Laryngeal Cancer
   Jeffrey J. Lehman, Vicki Lewis, Adam T. Lloyd, and Bari Hoffman Ruddy

15 Team Approach in Treating Laryngeal Cancer Resulting in Total Laryngectomy
   Jennifer Craig, Kyle Mannion, and C. Gaelyn Garrett

16 Eliminating Aspiration Risk Through Total Laryngectomy: A Surgical Approach
   Requiring Laryngectomy
   Linda Stachowiak

Part VI. Less Common Cases

17 Management of Nasopharyngeal Carcinoma
   Jeffrey E. Baylor, Christian E. Soto, and Vicki Lewis

18 Case of Occult Primary Head and Neck SCCA Presented With Lymphadenopathy
   Nikhil Rao, Vicki Lewis, Henry Ho, Aftab H. Patni, Erin P. Silverman, Lee Zehenbot, and
   Bari Hoffman Ruddy

Part VII. Consideration of Communication Options and Patient-Centered Treatment

19 Consideration of Communication Options in Head and Neck Cancer: Augmentative
   and Alternative
   Laura J. Ball, Jennifer Kent-Walsh, and Nancy A. Harrington

20 Rehabilitation of the Laryngectomized Individual: Alaryngeal Communication Options
   Bari Hoffman Ruddy, Vicki Lewis, and Christine Sapienza

21 Patient Life Experiences Essential for Humanistic and Quality Care
   Kathleen Ann Kavanagh

22 Health Literacy Implications for Head and Neck Cancer Patients
   Kristie Hadden, Richard I. Zraick, and Samuel R. Atcherson

Appendix A. Abbreviations

Appendix B. Consulted References for Glossary

Glossary

Index
In general, head and neck cancer (HNC) accounts for approximately 3% of new cases of cancer in the United States with a male-to-female ratio for HNC estimated as 4:1. The incidence of patient cases with HNC resulting from the use of tobacco products is dropping due to increased societal awareness and antitobacco education. However, the overall incidence of oropharyngeal HNC is increasing as a consequence of the human papillomavirus (HPV).

Assessment and treatment of HNC requires multidisciplinary and integrative care. HNC carries a considerable burden to patients and families, including costs associated with diagnosis, treatment, hospitalization, and medications. Aside from costs that are directly attributable to HNC, there is a considerable load imposed from secondary conditions such as disordered mechanisms of airway protection (cough and swallow). These conditions are nearly ubiquitous among HNC patients at the time of diagnosis and initial treatment, and persist in over half of patients with HNC 5 or more years following diagnosis. Taken alone or together, these conditions increase the likelihood of lung infection and death. A separate financial burden in the form of physician visits, hospitalization for lung infection, medications (particularly antibiotics) to treat the lung infection, and alternative modes of nutritional support (such as tube feeds) for patients with HNC may occur. Yet, by no means is the suffering from HNC and its sequela merely financial. Cancer, in all its forms, can exert devastating psychosocial and psycho-emotional effects on both patients and caregivers. For patients with HNC, disorders of airway protection transform eating and drinking, activities which are typically as pleasurable as they are necessary, into potential sources of embarrassment or rejection. This can lead to depression and isolation, both of which are factors that negatively impact quality of life (QoL). Health care professionals who treat patients with HNC have an obligation to continually improve the quality and effectiveness of our care. We are also obliged to explore and develop additional, effective, treatment options for our patients that can potentially lessen the financial and interpersonal burdens imposed by this disease.

There are limited resources that provide a comprehensive description of complex HNC cases. Therefore, this book was written by experts in otolaryngology, medical oncology, radiation oncology, speech pathology, nursing, radiology, and dietetics in order to provide a comprehensive presentation of the complexity of the patient with HNC. Health literacy, humanistic care approaches, and information pertaining to diagnostic and clinical concerns are presented to help successfully manage patients with HNC. The cases cover contemporary practice issues surrounding HPV, robotic or minimally invasive surgery, combined modality treatments, reflux management, and the critical role of the speech pathologist are threaded throughout the entire management process. Additionally, issues of survivorship and caregiver burden are included. Finally, unique intervention protocols are highlighted for airway protection along the continuum of prevention, pre-radiation, and post-radiation.

The multimedia component of this book is extraordinary, including complete cases with accompanying images (PET, MRI, CT), surgical video, treatment approaches, and so on. Our intended audience is for graduate education in speech pathology, medical school education, resident education, continuing education for practicing speech-language pathologists, nurse case managers, dieticians, and any person involved on a head and neck cancer team. The models of team practice demonstrate the commitment to the ideal treatment of HNC with the ultimate goal of preserving health and patient quality of life.
Acknowledgments

Florida Hospital Cancer Institute is recognized as one of America’s Best Hospitals in Cancer Treatment and is accredited as a Comprehensive Cancer Care Center. The authors’ affiliation with the Florida Hospital Cancer Institute, the premier nature of their care teams, and their whole person-centered approach motivated the creation of *Cases in Head and Neck Cancer: A Multidisciplinary Approach*. Ultimately, we hope our book will guide future clinicians to care for the patient with head and neck cancer in the most intelligent and respectful manner.

We are grateful to all of our authors for their wisdom and time spent creating a volume of work that documents their contemporary methods of assessment and treatment of patients with head and neck cancer. With their expert contributions, we are one step closer to helping educate the professional community on the distinct nature and needs of patients with head and neck cancer.
Contributors

**Vrushali Angadi, MS, CCC-SLP**
Clinical Speech-Language Pathologist
University of Kentucky Voice and Swallow Clinic
PhD Candidate, Rehabilitation Sciences
University of Kentucky
Lexington, Kentucky
*Chapter 6*

**Carl C. Askern, MD, FACS**
Director, Aesthetic Plastic Surgery Pavilion
Central California Ear, Nose & Throat
Medical Group
Assistant Clinical Professor
Department of Surgery, Plastic Surgery Section
University of California, San Francisco
Fresno, California
*Chapter 11*

**Annette N. Askren, MA, CCC-SLP**
Speech-Language Pathologist
Department of Veterans Affairs
Washington, District of Columbia
*Chapter 11*

**Samuel R. Atcherson, PhD**
Associate Professor
Department of Audiology and Speech Pathology
University of Arkansas at Little Rock
Adjunct Clinical Associate Professor
Department of Otolaryngology-Head and Neck Surgery
University of Arkansas for Medical Sciences
Little Rock, Arkansas
*Chapter 22*

**Laura J. Ball, PhD, CCC-SLP**
Director of Hearing and Speech Research
Children’s National Health System
Associate Professor of Pediatrics
George Washington University
Washington, District of Columbia
*Chapter 19*

**Jeffrey E. Baylor, MD, FACS**
Ear, Nose, Throat and Plastic Surgery Associates
Orlando, Florida
*Chapter 17*

**Angela L. Campanelli, MS, CCC-SLP, BCS-S**
Voice Pathologist
Dysphagia Specialist
Blaine Block Institute for Voice Analysis and Rehabilitation
Dayton, Ohio
*Chapter 10*

**Keith Casper, MD**
University of Michigan
Department of Otolaryngology-Head and Neck Surgery
Ann Arbor, Michigan
*Chapter 3*

**Jennifer Craig, MS, CCC-SLP**
Assistant in Otolaryngology
Vanderbilt Voice Center
Vanderbilt University Medical Center
Nashville, Tennessee
*Chapter 15*

**Elizabeth Feldman, MS, DMD**
Maxillofacial Prosthodontics
Dental Oncology
UF Health Cancer Center
Orlando Health
Orlando, Florida
*Chapter 7*

**Thomas J. Gal, MD, MPH, FACS**
Professor
Division of Head and Neck Surgery
University of Kentucky
Lexington, Kentucky
*Chapter 6*
C. Gaelyn Garrett, MD
Professor and Vice Chair
Department of Otolaryngology
Senior Executive Medical Director
Vanderbilt Voice Center
Vanderbilt University Medical Center
Nashville, Tennessee
Chapter 15

Matthew R. Garrett, MD, FACS
Southwest Ohio ENT Specialists, Inc.
Dayton, Ohio
Chapter 10

Douglas A. Girod, MD, FACS
Professor of Otolaryngology-Head and Neck Surgery
Executive Vice Chancellor
University of Kansas Medical Center
Kansas City, Kansas
Chapter 2

G. Brandon Gunn, MD
Assistant Professor
Radiation Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Chapter 5

Kristie Hadden, PhD
Assistant Professor
Director, Center for Health Literacy
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Chapter 22

Nancy A. Harrington, MA, CCC-SLP
Instructor
Department of Communication Sciences and Disorders
University of Central Florida
Florida Alliance for Assistive Services and Technology
Oviedo, Florida
Chapter 19

Henry Ho, MD, FACS
Director
Head and Neck Program
The Florida Hospital Cancer Institute
President
Ear, Nose, Throat and Plastic Surgery Associates
Associate Professor of Surgery
Florida State University College of Medicine
Associate Professor of Otolaryngology
University of Central Florida College of Medicine
Orlando, Florida
Chapters 1, 9, and 18

Bari Hoffman Ruddy, PhD, CCC-SLP
Associate Professor
Department of Communication Sciences and Disorders
University of Central Florida
Research Partner
Florida Hospital Cancer Institute
Director, Center for Voice Care and Swallowing Disorders
Ear, Nose, Throat and Plastic Surgery Associates
Orlando, Florida
Chapters 1, 9, 14, 18, and 20

Katherine A. Hutcheson, PhD
Assistant Professor
Department of Head and Neck Surgery
Associate Director of Research
Section of Speech Pathology and Audiology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Chapter 5

Kathleen Ann Kavanagh, DMH, MSN Ed RN
Director of Simulation Training Applied Research
Assistant Professor of Nursing
Brooks Rehabilitation College of Healthcare Sciences
School of Nursing
Jacksonville University
Jacksonville, Florida
Chapter 21

Jennifer Kent-Walsh, PhD, CCC-SLP, S-LP(C)
Professor
Communication Sciences and Disorders
Director
FAAST Atlantic Region Assistive Technology Demonstration Center
University of Central Florida
Orlando, Florida
Chapter 19

Bernice K. Klaben, PhD, CCC-SLP, BCS-S
Associate Professor
Department of Otolaryngology-Head and Neck Surgery
University of Cincinnati Medical Center
Cincinnati, Ohio
Chapter 3

Molly A. Knigge, MS, CCC-SLP, BCS-S
Manager
Adult Swallow, Voice and Swallow Clinics
University of Wisconsin, Madison
Madison, Wisconsin
Chapter 8

Mario A. Landera, SLPD, CCC-SLP, BCS-S
Instructor
Department of Otolaryngology
University of Miami
Miller School of Medicine
Miami, Florida
Chapter 4

Wendy D. LeBorgne, PhD, CCC-SLP
Voice Pathologist, Clinical Director
The Blaine Block Institute for Voice Analysis and Rehabilitation
The Professional Voice Center of Greater Cincinnati
Dayton, Ohio
Chapter 10

Jeffrey J. Lehman, MD, FACS
Medical Staff President
Florida Hospital
Medical Director
Center for Voice Care and Swallowing Disorders
Ear, Nose, Throat and Plastic Surgery Associates
Orlando, Florida
Chapters 1 and 14

Elizabeth Leon, MD
Physician
Malcolm Randal VA Medical Center
Assistant Professor
Department of Otolaryngology

University of Florida
Gainesville, Florida
Chapter 11

Vicki Lewis, MA, CCC-SLP
The Center for Voice Care and Swallowing Disorders
Ear, Nose, Throat and Plastic Surgery Associates
Orlando, Florida
Chapters 14, 17, 18 and 20

Adam T. Lloyd, MM, MA, CCC-SLP
Speech Pathologist
Ear, Nose, Throat and Plastic Surgery Associates
Voice Care Center
Orlando, Florida
Chapters 9, 13, and 14

Donna S. Lundy, PhD, CCC-SLP, BCS-S
Associate Professor
Department of Otolaryngology
University of Miami
Miller School of Medicine
Miami, Florida
Chapter 4

Kyle Mannion, MD, FACS
Assistant Professor
Department of Otolaryngology, Head and Neck Surgery
Vanderbilt University Medical Center
Nashville, Tennessee
Chapter 15

Annette H. May, MA, CCC-SLP, BCS-S
Speech Pathology Coordinator
Oncology
UF Health Cancer Center
Orlando Health
Orlando, Florida
Chapter 7

Timothy M. McCulloch, MD
Charles N. Ford Professor
Chairman, Division of Otolaryngology
Department of Surgery
UW School of Medicine and Public Health
Madison, Wisconsin
Chapter 8
William M. Mendenhall, MD
Professor
Department of Radiation Oncology
University of Florida
Gainesville, Florida
Chapter 11

Claudio F. Milstein, PhD, CCC-SLP
Associate Professor
Cleveland Clinic Lerner College of Medicine
Director, The Voice Center
Head and Neck Institute
Cleveland Clinic
Cleveland, Ohio
Chapter 12

Aftab H. Patni, MD
Ear, Nose, Throat and Plastic Surgery Associates
Orlando, Florida
Chapter 18

Kristen Pytynia, MD, MPH
Associate Professor
Department of Head and Neck Surgery
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Chapter 5

Nikhil Rao, MD
Associate Professor of Radiation Oncology
University of Central Florida College of Medicine
Radiation Oncology Specialists
Florida Hospital
Winter Park, Florida
Chapters 1 and 18

Jennifer R. Reitz, MS, CCC-SLP
Voice Pathologist
The Blaine Black Institute for Voice Analysis and Rehabilitation
Dayton, Ohio
Chapter 10

Charles E. Riggs, Jr., MD, FACP
Staff Physician, Medical Division
Clinical Professor
Division of Hematology–Oncology
Department of Medicine

University of Florida College of Medicine
Gainesville, Florida
Chapter 11

Jonathon O. Russell, MD
Head and Neck Institute
Cleveland Clinic
Cleveland, Ohio
Chapter 12

Christine Sapienza, PhD, CCC-SLP
Dean
Brooks Rehabilitation College of Healthcare Sciences
Jacksonville University
Jacksonville, Florida
Chapters 1 and 20

Zoukaa B. Sargi, MD, MPH
Associate Professor
Department of Otolaryngology
University of Miami
Miller School of Medicine
Miami, Florida
Chapter 4

Joseph Scharpf, MD, FACS
Head and Neck Institute
Cleveland Clinic Foundation
Associate Professor of Surgery
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
Chapter 12

Ilona M. Schmaulfuss, MD
Professor of Radiology
North Florida/South Georgia Veterans Administration
University of Florida
Gainesville, Florida
Chapter 11

Jeff Searl, PhD, CCC-SLP
Associate Professor
Hearing and Speech Department
University of Kansas Medical Center
Kansas City, Kansas
Chapter 2
Erin P. Silverman, PhD, CCC-SLP  
Research Assistant Professor  
Department of Physiological Sciences  
University of Florida  
Gainesville, Florida  
*Chapters 9, 13, 14, and 18*

Christian E. Soto, MM, CF-SLP  
The Center for Voice Care and Swallowing Disorders  
Ear, Nose, Throat and Plastic Surgery Associates  
Orlando, Florida  
*Chapter 17*

Brian C. Spector, MD, FACS  
Partner  
Ear, Nose, Throat and Plastic Surgery Associates  
Orlando, Florida  
*Chapter 13*

Linda Stachowiak, MS, CCC-SLP, BCS-S  
Speech Pathology Oncology Specialist  
UF Health Cancer Center  
Orlando Health  
Adjunct Instructor  
University of Central Florida  
Orlando, Florida  
*Chapter 16*

Joseph C. Stemple, PhD, CCC-SLP  
Professor  
Division of Communication Sciences and Disorders  
University of Kentucky  
Lexington, Kentucky  
*Chapter 6*

Paula A. Sullivan, MS, CCC-SLP, BCS-S  
Speech-Language Pathology Section, Neurology Service  
Malcom Randall VAMC  
North Florida/South Georgia Veteran’s Health System  
Gainesville, Florida  
*Chapter 11*

Terance Ted Tsue, MD, FACS  
Physician in Chief  
University of Kansas Cancer Center  
Douglas A. Girod MD Endowed Professor of Head and Neck Surgical Oncology  
Vice Chairman  
Department of Otolaryngology-Head and Neck Surgery  
Interim Chairman  
Department of Radiation Oncology  
University of Kansas School of Medicine  
Kansas City, Kansas  
*Chapter 2*

Lee Zehenbot, MD  
Florida Hospital Cancer Institute  
Florida Cancer Specialists  
Orlando, Florida  
*Chapter 18*

Richard I. Zraick, PhD, CCC-SLP  
Professor and Chair  
Department of Communication Sciences and Disorders  
University of Central Florida  
Orlando, Florida  
*Chapter 22*
Multimedia List

Chapter 2
Video 2–1A. Oral motor movements
Video 2–1B. Flap and fistula views
Video 2–1C. Forearm and leg donor sites
Video 2–2. Description of speech and communication difficulties
Video 2–3. History and spontaneous speech sample

Chapter 3
Audio 3–1 Audio recording of the Rainbow Passage
Audio 3–2. Audio recording of the CAPE V sentences one year post treatment
Audio 3–3. Audio recording of spontaneous conversation one year post treatment
Audio 3–4 Audio recording of the Rainbow Passage one year post treatment
Audio 3–5. Audio recording of sustained vowel production one year post treatment

Chapter 4
Video 4–1. Initial speech sample post CRT
Video 4–2. Initial Modified barium swallow (MBS) post CRT
Video 4–3. MBS 2 determining level of therapy improvement
Video 4–4. Nasendoscopy
Video 4–5. MBS 3 18 months post CRT

Chapter 5
Video 5–1. MBS pre CRT
Video 5–2. MBS 1 year post CRT 1Y
Video 5–3. MBS 5 years late RAD
Video 5–4. pre TORS endoscopy
Video 5–5. MBS pre TORS
Video 5–6. MBS post TORS
Video 5–7. Endoscopy post TORS PORT
Video 5–8. MBS post TORS PORT

Chapter 6
Video 6–1. Pre-operative oropharyngeal and laryngeal examination
Video 6–2. Post-operative oropharyngeal and laryngeal examination

Chapter 7
Video 7–1. Pre-treatment MBS
Video 7–2. Initial post-operative modified barium swallow
Video 7–3. MBS post-healing from chemoradiation
Video 7–4. Speech sample with patient using palatal augmentation prosthesis
Video 7–5. Speech sample of patient without palatal augmentation prosthesis
Video 7–6. Patient demonstrating eating solid foods with palatal augmentation prosthesis in place, use of baby spoon as adaptive equipment, head forward posture for bolus control, liquid wash to assist in bolus transfer, and breath hold for airway protection

Chapter 8
Video 8–1. Post-op Day 3 VFSS
Video 8–2. Post-op Day 37 FEES

Chapter 9
Video 9–1. A pre-treatment FEES examination
Video 9–2. A post treatment FEES examination
Chapter 10
- Video 10–1. Video laryngostroboscopy initial disease
- Video 10–2. Video laryngostroboscopy 10 week post CRT
- Video 10–3. FEES post Tx

Chapter 12
- Video 12–1. Videolaryngostroboscopy at 10 months post operative visit
- Video 12–2. Videolaryngostroboscopy at 45 months post operative visit

Chapter 13
- Video 13–1. The initial laryngostroboscopic examination
- Video 13–2. The initial postoperative laryngostroboscopic examination
- Video 13–3. A repeat laryngostroboscopic examination, 5 months post treatment

Chapter 15
- Video 15–1. Voice evaluation with laryngostroboscopy
- Video 15–2. Videolaryngostroboscopy revealing increased thickness and decreased mucosal wave of the left true vocal fold
- Video 15–3. Exophytic lesion with surrounding erythema and impaired mobility of the left true vocal fold.

Chapter 16
- Video 16–1. MBS pre treatment
- Video 16–2. MBS post treatment
- Video 16–3. Oral intake with modifications
- Video 16–4. Communicating with a tracheoesophageal voice prosthesis (TEP)

Chapter 17
- Video 17–1. Post treatment videofluoroscopic swallowing study video
To patients and their families surviving with Head and Neck Cancer
and to future clinicians who will have the privilege of treating and caring for these individuals.
PART I

Demographics and Definitions
INTRODUCTION

This introductory chapter reviews cancers of the head and neck (HNC) with particular focus on the most common variety of HNC, squamous cell carcinoma (HNSCC). Specifically, this chapter reviews:

- the incidence and prevalence of HNCs;
- the locations and varieties of HNCs;
- the primary causes and symptoms of HNSCC;
- the variety of HNSCC types and the disease staging process;
- treatment options for HNC, including:
  - surgery,
  - radiation,
  - chemotherapy, and
  - combined modality;
- the makeup of the multidisciplinary clinical and research team involved in the assessment and treatment of patients with HNC; and

HEAD AND NECK CANCER STATISTICS

Cancer is a class of diseases characterized as the uncontrolled growth of abnormal or malignant cells (National Cancer Institute, 2015). Cancer cells can arise anywhere in the human body, dividing beyond normal limits. Cancer cells may accumulate and form tumors, invade adjacent tissue or structures, and/or spread to other locations in the body via blood or the lymphatic system, a process referred to as metastasis. In 2015, the American Cancer Society estimated that there would be 59,340 new cases of HNC and that an estimated 12,290 people will die of this disease. Overall, HNC accounts for approximately 3% of new cases of cancer in the United States. The male-to-female ratio for HNC is estimated as 4:1 (Jemal, Siegel, Xu, & Ward, 2010).

HNC SITES

HNC can affect the skin, mucous membranes, glandular structures, neurovascular elements, and supportive soft tissues and bones in the head and neck. Leukoplakia, a white patch or plaque, is often the visible presentation of a precancerous lesion or early stage carcinoma, requiring biopsy in order to determine its characteristics. HNCs frequently emerge within the

- oral cavity: lips, floor of mouth, oral tongue, buccal mucosa, gingival, retromolar trigone**, and hard palate;
**Cases in Head and Neck Cancer: A Multidisciplinary Approach**

- oropharynx: tonsil, soft palate, base of tongue, and lateral/posterior pharyngeal wall;
- nasopharynx;
- hypopharynx: pyriform sinus;
- larynx: glottic, supraglottic, and subglottic;
- nasal cavity and paranasal sinuses;
- salivary glands: parotid, submandibular, sublingual, and minor salivary glands;
- ear: external ear, middle ear, and temporal bone;
- neck: thyroid gland and lymph nodes; and
- regional soft tissues and supporting bones.

**The retromolar trigone is a small mucosal area behind the last molar of the lower jaw. Cancer identified in this location often rapidly spreads to adjacent oral structures.**

**HEAD AND NECK SQUAMOUS CELL CANCERS**

Head and neck squamous cell cancer (HNSCC) originates within the mucous membranes of the nasal cavity, sinuses, lips, oral cavity, salivary glands, tongue, soft palate, pharynx, and larynx and is the fifth deadliest cancer worldwide (Chaukar et al., 2009; Lee, Wang, Mu-Hsin, Chang, & Chu, 2013; Ma et al., 2013; Melo Filho et al., 2013) with survival rates ranging from 30% for cancers of the oral cavity and pharynx to 50% for laryngeal cancers. Five-year survival rates from 2001 to 2007 indicated a 60.8% survival rate for laryngeal cancer, oral cavity and pharynx (Chaukar et al., 2009; Lee et al., 2013; LeTempi et al., 2005; http://surveillance.cancer.gov/publications/factsheets/SEER_Cancer_Survivor_Fact_Sheet.pdf). Approximately 95% of cancers of the oral cavity and the oropharynx are squamous cell carcinomas (Hsu et al., 2008; Snow, Wackym, & Ballenger, 2009; Spitz, 1994). A portion of squamous cell cancers test positive for the human papillomavirus (HPV-16). Squamous cell histologic grading includes keratinizing versus nonkeratinizing, and well-differentiated to poorly differentiated cellular characteristics. Variants of squamous cell cancer types can include undifferentiated carcinoma, lymphoepithelioma, spindle cell carcinoma, and verrucous carcinoma.

**PRIMARY CAUSES OF HNSCC**

The primary risk factors linked to the development of HNSCC are inhaled cigarette or marijuana smoke, pipe and cigar smoke, as well as chewing tobacco. The greatest risk occurs when anatomical areas and their susceptible epithelium are directly exposed to these toxins. The risk level is dependent on daily consumption, type, toxicity, and manner of tobacco use (Casper & Colton, 1998; Sapienza & Ruddy, 2012).
A synergistic effect exists when tobacco use is combined with consumption of alcohol, creating a higher risk of cancer development compared to if each was consumed independently. Although tobacco use and alcohol have consistently been implicated as a causative factor for HNC, it can develop in their absence; although it is significantly less common (Spitz, 1994). Additionally, although laryngopharyngeal reflux (LPR) has been largely implicated in esophageal disease, a recently identified relationship between severe LPR and HNC disease exists (Lipan, Reidenberg, & Laitman, 2006). Recent research shows that a portion of head and neck squamous cell cancers test positive for the human papillomavirus (HPV). There are numerous types of HPV; the type most frequently associated with oropharyngeal cancer is HPV-16. HPV-18 has also been associated with this cancer (Kreimer, Clifford, Boyle, & Franceschi, 2005). Studies have also found that oral HPV infections can be acquired through sexual contact (D’Souza et al., 2007). The incidence of these HPV-positive squamous cell carcinomas has increased in recent decades, especially in younger individuals. HPV-positive tumors have been associated with better survival rates than HPV-negative tumors (Ang et al., 2010). Please see Chapter 5 for contemporary and detailed information regarding HPV-positive tumors in the oropharynx.

**GENERAL CANCER STAGING**

**American Joint Committee on Cancer Staging (AJCC) Guidelines**

The TNM staging system developed by the American Joint Committee on Cancer (AJCC) Staging (http://www.cancerstaging.org) correlates with survival outcomes and is organized as follows:

- **T:** Tumor (extent of primary tumor)
  - TX: Primary tumor cannot be assessed
  - T0: No evidence of primary tumor
  - Tis: Carcinoma in situ
- **Stage 0**
  - Tis, N0, M0
- **Stage I**
  - T1, N0, M0
- **Stage II**
  - T2, N0, M0
- **Stage III**
  - T3, N0, M0
  - T1, N1, M0
  - T2, N1, M0
  - T3, N1, M0
- **Stage IVA**
  - T4a, N0, M0
  - T4a, N1, M0
  - T1, N2, M0
  - T2, N2, M0
  - T3, N2, M0
  - T4a, N2, M0
- **Stage IVB**
  - T4b, any N, M0
  - Any T, N3, M0
- **Stage IVC**
  - Any T, any N, M1

Tumor staging takes into account the size of a tumor, how deep it has penetrated, whether it has invaded adjacent organs, if it has metastasized to lymph nodes, and whether it has spread to distant organs. Management is typically prescribed and/or changed based on the stage at initial diagnosis or recurrence, and remains a powerful predictor of survival. The staging system is clinical, based on the best possible estimate of disease extent recorded before treatment. The assessment of the primary tumor is based on inspection and palpation, when possible, and by visual endoscopic/stroboscopic examination. In order to accurately stage the cancer, the tumor must be confirmed histologically by biopsy. Radiographic studies such as CT, MRI, or PET scans help delineate the degree of local extent, as well as potential regional lymphatic and distant metastatic spread (Mendenhall, Riggs, & Cassisi, 2005).
### Staging Supraglottic (Above the Vocal Folds) Cancer

- **T1:** Tumor limited to one subsite of supraglottis with normal vocal fold mobility
- **T2:** Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, or medial wall of piriform sinus) without fixation of the larynx
- **T3:** Tumor limited to larynx with vocal fold fixation and/or invades any of the following: postcricoid area, pre-epiglottic tissues, paraglottic space, and/or minor thyroid cartilage erosion (e.g., inner cortex)
- **T4a:** Tumor invades through the thyroid cartilage, and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of the neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)
- **T4b:** Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

Subsites Include the Following

- False vocal folds
- Arytenoids
- Suprahyoid epiglottis
- Infrahyoid epiglottis
- Aryepiglottic folds (laryngeal aspect)

### Staging Glottic (at the Level of the Vocal Folds) Cancer

Glottic presentation may vary by volume of tumor, anatomic region involved, and the presence or absence of normal vocal fold mobility:

- **T0:** No evidence of primary tumor
- **Tis:** Carcinoma in situ: confined to tissues lining the larynx
- **T1:** Tumor limited to the vocal fold(s), which may involve anterior or posterior commissure, with normal mobility
- **T1a:** Tumor limited to one vocal fold
- **T1b:** Tumor involves both vocal folds
- **T2:** Tumor extends to supraglottis and/or subglottis and/or with impaired vocal fold mobility
- **T3:** Tumor limited to the larynx with vocal fold fixation and/or invades paraglottic space, and/or minor thyroid cartilage erosion (e.g., inner cortex)
- **T4a:** Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck, including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)
- **T4b:** Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

### Staging of Subglottic (Below the Vocal Folds) Cancer

- **T1:** Tumor limited to the subglottis
- **T2:** Tumor extends to vocal fold(s) with normal or impaired mobility
- **T3:** Tumor limited to larynx with vocal fold fixation
- **T4a:** Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond...
the larynx (e.g., trachea, soft tissues of neck, including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)

- T4b: Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

### Staging of Oropharyngeal Cancer

- T1: Tumor is 2 cm (about three-quarter inch) across or smaller
- T2: Tumor is larger than 2 cm across but smaller than 4 cm (about 1 ½ inch)
- T3: Tumor is larger than 4 cm across. For cancers of the oropharynx, T3 also includes tumors that are growing into the epiglottis.
- T4a: Tumor is growing into nearby structures. This is known as *moderately advanced local disease*.
  - For oral cavity cancers: the tumor is growing into nearby structures, such as the bones of the jaw or face, deep muscle of the tongue, skin of the face, or the maxillary sinus.
  - For lip cancers: the tumor is growing into nearby bone, the inferior alveolar nerve (the nerve to the jawbone), the floor of the mouth, or the skin of the chin or nose.
  - For oropharyngeal cancers: the tumor is growing into the larynx (voice box), the tongue muscle, or bones such as the medial pterygoid, the hard palate, or the jaw.
- T4b: The tumor has grown through nearby structures and into deeper areas or tissues. This is known as *very advanced local disease*. Any of the following may be true:
  - The tumor is growing into other bones, such as the pterygoid plates and/or the skull base (for any oral cavity or oropharyngeal cancer).
  - The tumor surrounds the internal carotid artery (for any oral cavity or oropharyngeal cancer).
  - For lip and oral cavity cancers: the tumor is growing into an area called the *masticator space*.
  - For oropharyngeal cancers: the tumor is growing into a muscle called the *lateral pterygoid muscle*.
  - For oropharyngeal cancers: the tumor is growing into the nasopharynx (the area of the throat that is behind the nose).

### Staging of Nasopharyngeal Cancer

- T1: Tumor confined to the nasopharynx, or tumor extends to oropharynx and/or nasal cavity without parapharyngeal extension (e.g., without posterolateral infiltration of tumor)
- T2: Tumor with parapharyngeal extension (posterolateral infiltration of tumor)
- T3: Tumor involves bony structures of skull base and/or paranasal sinuses
- T4: Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, or orbit, or with extension to the infratemporal fossa/masticator space

### CANCER SPREAD

Cancer spread or *metastasis* refers to the migration of cancer cells from the site of initial presentation, to other areas of the body not previously involved. Cancer spread can be characterized as local, lymphatic, or hematogenous. Initial spread is usually regional, involving tissues adjacent to the tumor cells. Most primary tumors arise as surface lesions and spread by local invasion laterally as well as deeply, following a pathway of least resistance between fascial planes. Muscle tissue frequently becomes invaded by laryngeal and tongue cancers. Bone and cartilage can become invaded in serious, advanced cases.

Lymphatic and hematogenous spread refers to the processes of transport of cancer cells from the primary tumor, to remote locations throughout the body through lymph or blood. Lymphatic spread is the most common means of metastasis and occurs...